Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $784,436.

  • ProQR Therapeutics N.V's Depreciation & Amortization (CF) rose 3.82% to $784,436 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 2.50%. This contributed to the annual value of $3.0 million for FY2024, which is 8.54% up from last year.
  • ProQR Therapeutics N.V's Depreciation & Amortization (CF) amounted to $784,436 in Q3 2025, which was up 2.67% from $764,073 recorded in Q2 2025.
  • ProQR Therapeutics N.V's Depreciation & Amortization (CF)'s 5-year high stood at $784,436 during Q3 2025, with a 5-year trough of $589,265 in Q1 2023.
  • For the 3-year period, ProQR Therapeutics N.V's Depreciation & Amortization (CF) averaged around $724,443, with its median value being $750,676 (2024).
  • In the last 5 years, ProQR Therapeutics N.V's Depreciation & Amortization (CF) decreased by 15.95% in 2022 and then grew by 27.39% in 2024.
  • Over the past 5 years, ProQR Therapeutics N.V's Depreciation & Amortization (CF) (Quarterly) stood at $631,472 in 2021, then climbed by 20.85% to $763,145 in 2022, then grew by 2.64% to $783,284 in 2023, then declined by 8.46% to $717,027 in 2024, then grew by 3.82% to $784,436 in 2025.
  • Its Depreciation & Amortization (CF) stands at $784,436 for Q3 2025, versus $764,073 for Q2 2025 and $713,178 for Q1 2025.